Pulmatrix (PULM) said it will present “promising” new preclinical data about its inhaled antifungal drug PUR1900 at the North American Cystic Fibrosis Conference.
A preclinical study comparing PUR1900 to an orally taken reference product shows that PUR1900 offers a significant advantage over the current standard of care for treating fungal infections in the lungs, the company said Tuesday.
High oral doses are needed to get enough of the antifungal drug to the lungs through the bloodstream to fight the infection, resulting in the potential for severe side effects, such as liver toxicity. Pulmatrix’s inhaled drug PUR1900, which combines itraconazole with the company’s dry powder delivery technology, has the potential to solve these problems. The new study confirms the expected advantages of inhaled drug delivery, the company said.
The shares rose 6.4% on Tuesday morning.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.